Study In Patients With Kidney Cancer Treated With Sutent
- Registration Number
- NCT00873210
- Lead Sponsor
- Pfizer
- Brief Summary
Objective of this study is to increase knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib.
- Detailed Description
Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 121
Inclusion Criteria
- Consecutive patients with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
Exclusion Criteria
- Hypersensitivity to sunitinib malate or to any of the excipients
- Any other contraindication to the use of sunitinib malate (based on decision of the treating physician).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients treated with Sutent Sutent 125 consecutive patients in outpatient care with advanced or metastatic renal cell carcinoma, that are indicated for 1st or 2nd line anticancer therapy
- Primary Outcome Measures
Name Time Method Increased knowledge about safety, tolerability, quality of life and efficacy under conditions of routine use of sunitinib 36 months
- Secondary Outcome Measures
Name Time Method Incidence of new diagnosed hypothyroidism 36 months Safety of sunitinib malate in "real-life" setting 36 months Efficacy of sunitinib malate in "real-life" setting 36 months Incidence of new diagnosed hypertension 36 months Dose modifications 36 months
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇸🇰Zilina, Slovakia